NCT05946148View on ClinicalTrials.gov

Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)

CompletedOBSERVATIONAL
Enrollment

78

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

May 31, 2021

Study Completion Date

May 31, 2021

Conditions
Non-Alcoholic Fatty Liver DiseaseLiver Steatosis
Interventions
DRUG

Empagliflozin

Empagliflozin 10mg daily, as add-on to previous treatment regimen.

DRUG

Dulaglutide

Dulaglutide 1.5mg weekly, as add-on to previous treatment regimen

DRUG

Control Rx

Optimal anti-diabetic treatment excluding agents of the GLP1-ras or SGLT2-is families.

Trial Locations (1)

11527

"Hippocration General Hospital of Athens", Athens

All Listed Sponsors
collaborator

Alexandra Hospital, Athens, Greece

OTHER

collaborator

Hippocration General Hospital

OTHER

lead

National and Kapodistrian University of Athens

OTHER

NCT05946148 - Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18) | Biotech Hunter | Biotech Hunter